Sumi Toshiyuki, Nagahisa Yuta, Matsuura Keigo, Sekikawa Motoki, Yamada Yuichi, Nakata Hisashi, Chiba Hirofumi
Department of Pulmonary Medicine Hakodate Goryoukaku Hospital Hakodate Japan.
Department of Respiratory Medicine and Allergology Sapporo Medical University School of Medicine Sapporo Japan.
Respirol Case Rep. 2021 Oct 24;9(11):e0868. doi: 10.1002/rcr2.868. eCollection 2021 Nov.
Immune checkpoint inhibitors (ICIs) have been used for various carcinomas. However, immune-related adverse events have been observed. There have been few reports of treatment with biologics for severe bronchial asthma induced by ICI; therefore, their efficacy is unknown. We report two cases of severe bronchial asthma requiring systemic steroid administration while using anti-programmed death-ligand 1 (PD-L1) antibody for advanced non-small-cell lung cancer. The anti-interleukin-5 antibody, mepolizumab, was introduced, resulting in the discontinuation of systemic prednisolone and good asthma control. These reports suggest that treatment with biologics may be effective in severe cases of poorly controlled bronchial asthma during ICI therapy.
免疫检查点抑制剂（ICIs）已被用于多种癌症。然而，已观察到免疫相关不良事件。关于使用生物制剂治疗ICI诱发的严重支气管哮喘的报道很少；因此，其疗效尚不清楚。我们报告了两例在使用抗程序性死亡配体1（PD-L1）抗体治疗晚期非小细胞肺癌时需要全身使用类固醇的严重支气管哮喘病例。引入抗白细胞介素-5抗体美泊利单抗后，全身泼尼松龙停用，哮喘得到良好控制。这些报告表明，在ICI治疗期间，生物制剂治疗对严重的、控制不佳的支气管哮喘病例可能有效。
